PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.

ABSTRACT:

Aims

This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real-world setting in Spain as part of the 13-country PIONEER REAL programme.

Materials and methods

This multicentre, prospective, non-interventional, single-arm study (NCT05443334) followed participants for 34-44 weeks. Participants were treated as part of routine clinical practice and were naïve to injectable glucose-lowering medication. The primary endpoint was the change in glycated haemoglobin (HbA_1c) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, the proportion of participants with HbA_1c <7% at EOS, and treatment satisfaction. Selected outcomes were stratified (post hoc) by sodium-glucose co

SUBMITTER: Delgado Alvarez E 

PROVIDER: S-EPMC12326947 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature